Antisense compounds, compositions and methods are provided for modulating the expression of Phosphorylase kinase alpha 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phosphorylase kinase alpha 2. Methods of using these compounds for modulation of Phosphorylase kinase alpha 2 expression and for treatment of diseases associated with expression of Phosphorylase kinase alpha 2 are provided.
Claims What is claimed is: 1. An antisense compound 8 to 30 nucleobases in length targeted to nucleobases 250 through 4524 of a coding region, or nucleobases 4150 through 4524 of a 3'-untranslated region of a nucleic acid molecule encoding human Phosphorylase kinase alpha 2 of SEQ ID NO: 3, wherein said antisense compound specifically hybridizes with one of said regions and inhibits the expression of human Phosphorylase kinase alpha 2. 2. The antisense compound of claim 1 which is an antisense oligonucleotide. 3. A antisense compound up to 30 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO: 28, 29, 30, 31, 32, 33, 35, 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 89, 90, 91, 92, 95, 96, 97, 98, 100, 101, 102, 103, 104 or 105 which inhibits the expression of human Phosphorylase kinase alpha 2. 4. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 5. The antisense compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage. 6. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 7. The antisense compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 8. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 9. The antisense compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine. 10. The antisense compound of claim 1 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 11. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 12. The composition of claim 11 further comprising a colloidal dispersion system. 13. The composition of claim 11 wherein the antisense compound is an antisense oligonucleotide. 14. A method of inhibiting the expression of human Phosphorylase kinase alpha 2 in cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 1 so that expression of human Phosphorylase kinase alpha 2 is inhibited. 15. The antisense compound of claim 3 which is an antisense oligonucleotide. 16. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 17. The antisense compound of claim 16 wherein the modified internucleoside linkage is a phosphorothioate linkage. 18. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 19. The antisense compound of claim 18 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 20. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 21. The antisense compound of claim 20 wherein the modified nucleobase is a 5-methylcytosine. 22. The antisense compound of claim 15 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 23. A method of inhibiting the expression of human Phosphorylase kinase alpha 2 in human cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 3 so that expression of human Phosphorylase kinase alpha 2 is inhibited. 24. A composition comprising the antisense compound of claim 3 and a pharmaceutically acceptable carrier or diluent. 25. The composition of claim 24 further comprising a colloidal dispersion system. 26. The composition of claim 24 wherein the antisense compound is an antisense oligonucleotide. 